A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.
Advanced Solid Tumor
DRUG: SHR-1701
Adverse events, Number of subjects with adverse events (AEs), Screening up to study completion, an average of 1 year|Laboratory results, Number of subjects with laboratory tests findings of potential clinical importance, Screening up to study completion, an average of 1 year|Vital signs, Incidence of vital sign abnormalities, Screening up to study completion, an average of 1 year|Electrocardiogram, Number of subjects with clinically significant abnormal ECG QT Interval, Screening up to study completion, an average of 1 year
Pharmacokinetic - Cmax, Maximum observed plasma concentration (Cmax) of SHR-1701, Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15|Pharmacokinetic - AUC∞, Area under the concentration-time curve from time 0 to infinity of SHR-1701, Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15|Pharmacokinetic - Tmax, Time to Cmax of SHR-1701, Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15|Pharmacokinetic - CL/F, Apparent clearance of SHR-1701, Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15|Pharmacokinetic - Vz/F, Apparent volume of distribution during terminal phase of SHR-1701, Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15|Pharmacokinetic - t1/2, Terminal elimination half-life, Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15|Pharmacodynamics- ADA, Anti-drug antibody of PD-L1, Pre-dose on Day1 of cycle 2,3,4,5,7,9,13,17
This is a two-part, open-label, multicenter, non-randomized, dose escalation, Phase 1 study of repeated doses of SHR-1701 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies.